MX2022004203A - Profarmacos de inhibidores de mieloperoxidasa. - Google Patents
Profarmacos de inhibidores de mieloperoxidasa.Info
- Publication number
- MX2022004203A MX2022004203A MX2022004203A MX2022004203A MX2022004203A MX 2022004203 A MX2022004203 A MX 2022004203A MX 2022004203 A MX2022004203 A MX 2022004203A MX 2022004203 A MX2022004203 A MX 2022004203A MX 2022004203 A MX2022004203 A MX 2022004203A
- Authority
- MX
- Mexico
- Prior art keywords
- prodrugs
- mpo
- myeloperoxidase
- inhibitors
- methods
- Prior art date
Links
- 239000000651 prodrug Substances 0.000 title abstract 4
- 229940002612 prodrug Drugs 0.000 title abstract 4
- 229940122159 Myeloperoxidase inhibitor Drugs 0.000 title 1
- 102000003896 Myeloperoxidases Human genes 0.000 abstract 3
- 108090000235 Myeloperoxidases Proteins 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000001089 Multiple system atrophy Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962913417P | 2019-10-10 | 2019-10-10 | |
| PCT/US2020/054896 WO2021072140A1 (en) | 2019-10-10 | 2020-10-09 | Prodrugs of myeloperoxidase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022004203A true MX2022004203A (es) | 2022-07-04 |
Family
ID=75438074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022004203A MX2022004203A (es) | 2019-10-10 | 2020-10-09 | Profarmacos de inhibidores de mieloperoxidasa. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240067651A1 (https=) |
| EP (1) | EP4041735A4 (https=) |
| JP (1) | JP2022552834A (https=) |
| KR (1) | KR20220080133A (https=) |
| CN (1) | CN114945573A (https=) |
| AU (1) | AU2020363903A1 (https=) |
| BR (1) | BR112022006381A2 (https=) |
| CA (1) | CA3157260A1 (https=) |
| IL (1) | IL291891A (https=) |
| MX (1) | MX2022004203A (https=) |
| WO (1) | WO2021072140A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021178734A1 (en) * | 2020-03-05 | 2021-09-10 | Biohaven Therapeutics Ltd. | Method of treating amyotrophic lateral sclerosis with myeloperoxidase inhibitor |
| CN115403584B (zh) * | 2021-05-26 | 2024-04-02 | 长春金赛药业有限责任公司 | 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5436790A (en) * | 1989-04-19 | 1990-11-16 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Sulfer-containing xanthine derivatives as adenosin antagonists |
| MY140748A (en) * | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| WO2007069924A1 (en) * | 2005-12-15 | 2007-06-21 | Industrial Research Limited | Deazapurine analogs of 4'-aza-l-nucleosides |
| NZ544187A (en) * | 2005-12-15 | 2008-07-31 | Ind Res Ltd | Deazapurine analogs of 1'-aza-l-nucleosides |
| US20090054468A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
| ES2691671T3 (es) * | 2010-06-24 | 2018-11-28 | Alkermes Pharma Ireland Limited | Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato |
| JP6667092B2 (ja) * | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体 |
| WO2016140879A1 (en) * | 2015-03-03 | 2016-09-09 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzole prodrugs and their use |
| AU2018304508B2 (en) * | 2017-07-17 | 2021-06-10 | Astrazeneca Ab | MPO inhibitors for use in medicine |
-
2020
- 2020-10-09 CA CA3157260A patent/CA3157260A1/en active Pending
- 2020-10-09 KR KR1020227015015A patent/KR20220080133A/ko not_active Withdrawn
- 2020-10-09 AU AU2020363903A patent/AU2020363903A1/en not_active Abandoned
- 2020-10-09 CN CN202080070666.8A patent/CN114945573A/zh active Pending
- 2020-10-09 MX MX2022004203A patent/MX2022004203A/es unknown
- 2020-10-09 JP JP2022521147A patent/JP2022552834A/ja active Pending
- 2020-10-09 EP EP20874337.7A patent/EP4041735A4/en not_active Withdrawn
- 2020-10-09 US US17/766,539 patent/US20240067651A1/en not_active Abandoned
- 2020-10-09 WO PCT/US2020/054896 patent/WO2021072140A1/en not_active Ceased
- 2020-10-09 IL IL291891A patent/IL291891A/en unknown
- 2020-10-09 BR BR112022006381A patent/BR112022006381A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021072140A1 (en) | 2021-04-15 |
| IL291891A (en) | 2022-06-01 |
| KR20220080133A (ko) | 2022-06-14 |
| AU2020363903A1 (en) | 2022-03-24 |
| BR112022006381A2 (pt) | 2022-06-28 |
| US20240067651A1 (en) | 2024-02-29 |
| CN114945573A (zh) | 2022-08-26 |
| JP2022552834A (ja) | 2022-12-20 |
| EP4041735A4 (en) | 2023-11-22 |
| CA3157260A1 (en) | 2021-04-15 |
| EP4041735A1 (en) | 2022-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| EP4245367A3 (en) | Methods for treating cholestasis | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| WO2021021979A3 (en) | Hdac6 inhibitors and uses thereof | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| WO2019236775A8 (en) | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | |
| MY207223A (en) | Prodrug modulators of the integrated stress pathway | |
| MX2022007968A (es) | Dosificacion de gamma-hidroxibutirato (ghb). | |
| JOP20220092A1 (ar) | جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر | |
| MY155633A (en) | Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy | |
| EP4302764A3 (en) | C17, c20, and c21 substituted neuroactive steroids and their methods of use | |
| GEP20227446B (en) | New catecholamine prodrugs for use in treatment of parkinson's disease | |
| PH12021550443A1 (en) | Pyridazinones and methods of use thereof | |
| MX2022002198A (es) | Composiciones y métodos para modular el empalme y la expresión de proteínas. | |
| MX2021002305A (es) | Tratamiento de trastornos del higado. | |
| MX2024010655A (es) | Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| MX2021000977A (es) | Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos. | |
| EP4279127A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
| MX2019012086A (es) | Composiciones y métodos para tratar o prevenir trastornos relacionados con la permeabilidad intestinal. | |
| MX2021003689A (es) | Farmacos precursores de antagonistas del peptido relacionado con el gen para calcitonina (gcrp). | |
| EP4640698A3 (en) | Antibodies to mucin-16 and methods of use thereof | |
| MX2023005971A (es) | Metodos y composicion para las modificaciones de kras. | |
| MX2022004203A (es) | Profarmacos de inhibidores de mieloperoxidasa. | |
| MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. |